The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success

References

• Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864.
   PubMed Web of Science ®Google Scholar
• Shetty A, Syn WK. Health and economic burden of nonalcoholic fatty liver disease in the United States and its impact on veterans. Federal practitioner: for the health care professionals of the VA, DoD, and PHS. 2019;36(1):14–19.
   Google Scholar
• [cited 2020 Oct 23]. Available from: https://www.reportsanddata.com/report-detail/non-alcoholic-steatohepatitis-nash-market
   Google Scholar
• Diehl AM, Harrison S, Caldwell S, et al. JKB-121 in patients with nonalcoholic steatohepatitis: A phase 2 double blind randomized placebo control study. J Hepatol. 2018;68:S103–S.
   Web of Science ®Google Scholar
• Gehrke N, Schattenberg JM. Metabolic inflammation-a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology. 2020;158(7):1929–47.e6.
   PubMed Web of Science ®Google Scholar
• Labenz C, Huber Y, Kalliga E, et al. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. Aliment Pharmacol Ther. 2018;48(10):1109–1116.
   PubMed Web of Science ®Google Scholar
• Kim D, Vazquez-Montesino LM, Li AA, et al. Inadequate physical activity and sedentary behavior are independent predictors of nonalcoholic fatty liver disease. Hepatology. 2020 Feb 3. DOI:10.1002/hep.31158. Epub ahead of print. PMID:32012316.
   Web of Science ®Google Scholar
• Carlsson B, Lindén D, Brolén G, et al. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2020;51(12):1305–1320.
   PubMed Web of Science ®Google Scholar
• Gehrke N, Wörns MA, Huber Y, et al. Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors. J Hepatol. 2016;65(6):1188–1197.
   PubMed Web of Science ®Google Scholar
• Armandi A, Schattenberg JM. NAFLD between genes and environment: what drives fibrogenesis? Gut. 2020. DOI:10.1136/gutjnl-2020-321964.
   PubMed Web of Science ®Google Scholar
• Ratziu V. A critical review of endpoints for non-cirrhotic NASH therapeutic trials. J Hepatol. 2018;68(2):353–361.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65(5):1557–1565.
   PubMed Web of Science ®Google Scholar
• Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, et al. Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis. Hepatology. 2019;69(5):2241–2257.
   PubMed Web of Science ®Google Scholar
• Labenz C, Huber Y, Michel M, et al. Impact of NAFLD on the incidence of cardiovascular diseases in a primary care population in Germany. Dig Dis Sci. 2020;65(7):2112–2119.
   PubMed Web of Science ®Google Scholar
• Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1611–25 e12.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184–2196.
   PubMed Web of Science ®Google Scholar
• Younossi Z. Emerging research on MGL-3196 for the treatment of nonalcoholic steatohepatitis. Gastroenterol Hepatol. 2019;15(6):317–319.
   Google Scholar
• Struik D, Dommerholt MB, Jonker JW. Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application. Curr Opin Lipidol. 2019;30(3):235–243.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Sanyal A, Francque S, et al. Cenicriviroc treatment for adults with non-alcoholic steatohepatitis: year 2 analysis of the phase 2b CENTAUR study. J Hepatol. 2018;68:S1–S2.
   Web of Science ®Google Scholar
• Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol. 2020;73(1):26–39.
   PubMed Web of Science ®Google Scholar
• Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018;67(2):549–559.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Noureddin M. STELLAR 3 and STELLAR 4: lessons from the fall of Icarus. J Hepatol. 2020;73(1):9–11.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Abdelmalek MF, Caldwell S, et al. Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology. 2018;155(4):1140–1153.
   PubMed Web of Science ®Google Scholar
• Segal-Salto M, Barashi N, Katav A, et al. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Rep. 2020;2(1):100064.
   PubMedGoogle Scholar
• [cited 2020 Oct 23]. Available from: https://www.globenewswire.com/news-release/2016/09/29/875865/0/en/Cempra-Announces-Anti-NASH-Effects-of-Solithromycin-Interim-Results-From-Phase-2-Study.html
   Google Scholar
• Sumati N. FDA Introductory Remarks NDA 209006 Solithromycin Capsules NDA 209007 Solithromycin Injection. Antimicrobial Drugs Advisory Committee Meeting. 2016 Nov 4. Available from: https://www.fda.gov/media/101570/download
   Google Scholar
• [cited 2020 Oct 23]. Available from: https://seekingalpha.com/news/3247047-cempras-solithromycin-fails-to-match-standard-of-care-in-gc-study-development-in-nash
   Google Scholar
• Wagner B, Tran P, Pagarigan R, et al. RG-125 (AZD4076): clinical candidate with a novel modality to treat insulin resistance through inhibiting miR-103/107. Diabetologia. 2015;58:S396–S.
   Web of Science ®Google Scholar
• Bates J, Vijayakumar A, Ghoshal S, et al. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J Hepatol. 2020 Oct;73(4):896–905. DOI:10.1016/j.jhep.2020.04.037. Epub 2020 May 4. PMID:32376414.
   Web of Science ®Google Scholar
• Lawitz EJ, Coste A, Poordad F, et al. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2018;16(12):1983–91.e3.
   PubMed Web of Science ®Google Scholar
• Loomba R, Kayali Z, Noureddin M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology. 2018;155(5):1463–73.e6.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Oct 23]. Available from: https://www.novumpr.nl/2019/12/16/gilead-announces-topline-results-from-phase-2-atlas-study-in-patients-with-bridging-fibrosis-f3-and-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash/
   Google Scholar
• Patel K, Harrison SA, Elkhashab M, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology. 2020;72(1):58–71.
   PubMed Web of Science ®Google Scholar
• [cited 2020 Oct 23]. Available from: https://www.clinicaltrialsarena.com/news/boehringer-drops-nash-development/
   Google Scholar
• [cited 2020 Oct 23]. Available from: https://pipelinereview.com/index.php/2019022570608/Small-Molecules/Boehringer-Ingelheim-Completes-Enrollment-of-Phase-2a-Clinical-Trial-of-Pharmaxis-Developed-Drug-in-NASH.html
   Google Scholar
• Garcia-Tsao G, Bosch J, Kayali Z, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol. 2020;72(5):885–895.
   PubMed Web of Science ®Google Scholar
• Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol. 2020;72(5):816–827.
   PubMedGoogle Scholar
• Westerouen Van Meeteren MJ, Drenth JPH, Tjwa E. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29(2):117–123.
   PubMed Web of Science ®Google Scholar
• Ratziu V, Harrison SA, Francque S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150(5):1147–59.e5.
   PubMed Web of Science ®Google Scholar
• Available from: https://pharmaphorum.com/news/genfits-nash-hopes-are-dashed-by-phase-3-trial-fail/
   Google Scholar
• Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006 [cited 2020 Oct 23]. A;116(11):3015–3025.
   PubMed Web of Science ®Google Scholar
• Fabbiano S, Suárez-Zamorano N, Chevalier C, et al. Functional Gut microbiota remodeling contributes to the caloric restriction-induced metabolic improvements. Cell Metab. 2018;28(6):907–21.e7.
   PubMed Web of Science ®Google Scholar
• Sutter AG, Palanisamy AP, Lench JH, et al. Dietary saturated fat promotes development of hepatic inflammation through toll-like receptor 4 in mice. J Cell Biochem. 2016;117(7):1613–1621.
   PubMed Web of Science ®Google Scholar
• Sharifnia T, Antoun J, Verriere TG, et al. Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol. 2015;309(4):G270–8.
   PubMed Web of Science ®Google Scholar
• Cengiz M, Ozenirler S, Elbeg S. Role of serum toll-like receptors 2 and 4 in non-alcoholic steatohepatitis and liver fibrosis. J Gastroenterol Hepatol. 2015;30(7):1190–1196.
   PubMed Web of Science ®Google Scholar
• Staufer K, Halilbasic E, Spindelboeck W, et al. Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. United European Gastroenterol J. 2019;7(8):1113–1123.
   PubMed Web of Science ®Google Scholar
• Haedrich M, Dufour JF. UDCA for NASH: end of the story? J Hepatol. 2011;54(5):856–858.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Nasr P, Kechagias S. Natural history of NAFLD/NASH. Curr Hepatol Rep. 2017;16(4):391–397.
   PubMedGoogle Scholar
• Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. JAMA Network Open. 2019;2(10):e1912565.
   PubMed Web of Science ®Google Scholar
• Davison BA, Harrison SA, Cotter G, et al. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol. 2020.
   Web of Science ®Google Scholar
• Schattenberg JM, Straub BK. On the value and limitations of liver histology in assessing non-alcoholic steatohepatitis. J Hepatol. 2020.
   Web of Science ®Google Scholar
• Liu F, Goh GB, Tiniakos D, et al. qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis. Hepatology. 2020;71(6):1953–1966.
   PubMed Web of Science ®Google Scholar
• Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology. 2019;70(6):1885–1888.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Therapeutic Landscape for NAFLD in 2020. Gastroenterology. 2020;158(7):1984–98.e3.
   PubMed Web of Science ®Google Scholar
• Glass O, Filozof C, Noureddin M, et al. Standardisation of diet and exercise in clinical trials of NAFLD-NASH: recommendations from the Liver Forum. J Hepatol. 2020 Sep;73(3):680–693. DOI:10.1016/j.jhep.2020.04.030. Epub 2020 Apr 27. PMID:32353483.
   Web of Science ®Google Scholar
• Sumida Y, Okanoue T, Nakajima A. Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis. Hepatol Res. 2019;49(11):1256–1262.
   PubMed Web of Science ®Google Scholar
• Schattenberg JM. Prof Jörn Schattenberg sheds light on key treatment and diagnostic approaches to nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29(2):111–113.
   PubMed Web of Science ®Google Scholar
• Siddiqui MS, Harrison SA, Abdelmalek MF, et al. Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 2018;67(5):2001–2012.
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209.
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Ye FZ, Li YY, et al. Individualized risk prediction of significant fibrosis in non-alcoholic fatty liver disease using a novel nomogram. United European Gastroenterol J. 2019;7(8):1124–1134.
   PubMed Web of Science ®Google Scholar